バーチャル臨床試験市場 - 世界の産業規模、シェア、動向、機会、予測、試験デザイン別、適応症別、フェーズ別、規制イオン別、競合別、2020年～2030年

バーチャル臨床試験の世界市場規模は2024年に84億8,000万米ドル、2030年までには157億6,000万米ドルに達し、CAGR10.86％で拡大すると予測されています。

バーチャル臨床試験（VCTs）は、分散型または遠隔試験とも呼ばれ、遠隔登録、モニタリング、データ収集にデジタルツールを活用することで、臨床研究方法に革命をもたらしています。このような臨床試験は、患者へのアクセスを改善し、リアルタイムのデータ収集を強化し、試験運営を合理化します。VCTの採用は、技術の進歩、患者中心の臨床試験モデルの推進、効率的で柔軟な試験デザインの必要性によって推進されています。現地訪問の必要性を排除することで、VCTは参加への障壁を減らし、試験の包括性を向上させます。データプライバシーや規制の複雑さをめぐる課題にもかかわらず、バーチャルモデルは従来の臨床試験の制限に対する持続可能なソリューションとして支持を集めており、グローバルな研究イニシアチブのスケーラビリティと運用効率を高めています。

主要な市場促進要因

疾病負担の増大

主要な市場課題

データセキュリティとプライバシー

主要市場動向

遠隔モニタリングとウェアラブル

目次

第1章 サービス概要

• 市場の定義
• 市場の範囲
  • 対象市場
  • 調査対象年
  • 主要市場セグメンテーション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のバーチャル臨床試験市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 試験デザイン別（介入研究、観察研究、拡大アクセス研究）
  • 適応症別（腫瘍学、心血管疾患、その他）
  • フェーズ別（フェーズ1、フェーズ2、フェーズ3、フェーズ4）
  • 企業別（2024年）
  • 地域別
• 市場マップ

第6章 北米のバーチャル臨床試験市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のバーチャル臨床試験市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋のバーチャル臨床試験市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のバーチャル臨床試験市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのバーチャル臨床試験市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 PESTEL分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Medable, Inc.
• ICON, plc
• Parexel International Corporation
• Medidata Solutions Inc
• Oracle Corp
• Signant Health
• Leo Laboratories Ltd
• IQVIA Inc
• PRA Health Sciences Inc
• Clinical Ink Inc

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global Virtual Clinical Trials Market was valued at USD 8.48 billion in 2024 and is projected to reach USD 15.76 billion by 2030, expanding at a CAGR of 10.86%. Virtual clinical trials (VCTs), also referred to as decentralized or remote trials, are revolutionizing the clinical research process by leveraging digital tools for remote enrollment, monitoring, and data collection. These trials improve patient accessibility, enhance real-time data capture, and streamline study operations. The adoption of VCTs is being driven by technological advancements, the push for patient-centric trial models, and the need for efficient, flexible study designs. By eliminating the requirement for physical site visits, VCTs reduce barriers to participation and improve trial inclusivity. Despite challenges around data privacy and regulatory complexities, the virtual model is gaining traction as a sustainable solution to traditional trial limitations, offering enhanced scalability and operational efficiency across global research initiatives.

Key Market Drivers

Growing Burden of Diseases

The rising incidence of chronic and rare diseases worldwide is a major driver fueling the adoption of Virtual Clinical Trials (VCTs). In 2024, over 828 million adults were reported to have diabetes, with nearly half of them untreated, indicating an urgent demand for more efficient research methodologies. Additionally, around 300 million people globally suffer from rare diseases. Traditional clinical trial models often encounter challenges like delayed recruitment and participant dropout, which can hinder medical advancements. VCTs offer a solution by using digital tools to reach broader and more diverse populations, thereby improving trial inclusivity and data relevance. The remote nature of VCTs is particularly advantageous for rare disease research, as these conditions often involve small, geographically dispersed patient groups. VCTs also expedite data collection and allow for real-time monitoring, enabling faster decision-making and adaptive trial protocols. To fully capitalize on these benefits, collaboration among stakeholders is necessary to maintain scientific rigor and regulatory compliance while improving access and outcomes.

Key Market Challenges

Data Security and Privacy

Data security and privacy are key concerns in the Virtual Clinical Trials (VCTs) market due to the extensive use of digital platforms for collecting and managing sensitive health information. The remote and tech-driven model of VCTs introduces heightened risks related to data breaches, unauthorized access, and the potential exposure of personally identifiable health data. Compliance with data protection regulations such as GDPR and HIPAA is particularly complex in multi-regional trials with varied regulatory landscapes. Addressing these issues requires robust encryption standards, secure communication protocols, and multi-factor authentication systems to protect patient data. Informed consent must be transparent and comprehensive, clearly outlining data usage and protection measures. Partnerships between technology providers, regulatory bodies, and cybersecurity experts are essential for establishing reliable frameworks that uphold data integrity and patient trust. Without strong safeguards, breaches can undermine the credibility of VCTs and stall their broader adoption.

Key Market Trends

Remote Monitoring and Wearables

The integration of remote monitoring and wearable devices is a transformative trend reshaping the Virtual Clinical Trials (VCTs) landscape. Wearables such as smartwatches and fitness trackers facilitate continuous, real-time health monitoring in everyday settings, offering rich datasets on parameters like heart rate, activity levels, and sleep patterns. This capability reduces the need for frequent site visits while improving trial accuracy through the collection of objective data. The ability to detect early signs of adverse reactions enhances patient safety and allows for proactive interventions. Additionally, remote monitoring promotes patient engagement by empowering individuals to take an active role in their health journey, which can boost trial adherence. The real-world insights gathered through these devices provide a more holistic view of treatment efficacy and patient experience. However, issues such as data integration, device interoperability, and accuracy must be addressed. Despite these hurdles, wearable-enabled monitoring is enhancing the depth and relevance of clinical trial data, contributing to more effective and efficient studies.

Key Market Players

• Medable, Inc.
• ICON, plc
• Parexel International Corporation
• Medidata Solutions Inc
• Oracle Corp
• Signant Health
• Leo Laboratories Ltd
• IQVIA Inc
• PRA Health Sciences Inc
• Clinical Ink Inc

Report Scope:

In this report, the Global Virtual Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Virtual Clinical Trials Market, By Study Design:

• Interventional
• Observational
• Expanded Access

Virtual Clinical Trials Market, By Indication:

• Oncology
• Cardiovascular Disease
• Others

Virtual Clinical Trials Market, By Phase:

• Phase 1
• Phase 2
• Phase 3
• Phase 4

Virtual Clinical Trials Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Virtual Clinical Trials Market.

Available Customizations:

Global Virtual Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customers

5. Global Virtual Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Study Design (Interventional, Observational, Expanded Access)
  • 5.2.2. By Indication (Oncology, Cardiovascular Disease, Others)
  • 5.2.3. By Phase (Phase 1, Phase 2, Phase 3, Phase 4)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Virtual Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Study Design
  • 6.2.2. By Indication
  • 6.2.3. By Phase
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Virtual Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Study Design
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Phase
  • 6.3.2. Mexico Virtual Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Study Design
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Phase
  • 6.3.3. Canada Virtual Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Study Design
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Phase

7. Europe Virtual Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Study Design
  • 7.2.2. By Indication
  • 7.2.3. By Phase
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Virtual Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Study Design
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Phase
  • 7.3.2. Germany Virtual Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Study Design
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Phase
  • 7.3.3. United Kingdom Virtual Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Study Design
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Phase
  • 7.3.4. Italy Virtual Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Study Design
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Phase
  • 7.3.5. Spain Virtual Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Study Design
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Phase

8. Asia-Pacific Virtual Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Study Design
  • 8.2.2. By Indication
  • 8.2.3. By Phase
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Virtual Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Study Design
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Phase
  • 8.3.2. India Virtual Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Study Design
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Phase
  • 8.3.3. South Korea Virtual Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Study Design
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Phase
  • 8.3.4. Japan Virtual Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Study Design
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Phase
  • 8.3.5. Australia Virtual Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Study Design
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Phase

9. South America Virtual Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Study Design
  • 9.2.2. By Indication
  • 9.2.3. By Phase
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Virtual Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Study Design
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Phase
  • 9.3.2. Argentina Virtual Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Study Design
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Phase
  • 9.3.3. Colombia Virtual Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Study Design
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Phase

10. Middle East and Africa Virtual Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Study Design
  • 10.2.2. By Indication
  • 10.2.3. By Phase
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Virtual Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Study Design
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Phase
  • 10.3.2. Saudi Arabia Virtual Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Study Design
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Phase
  • 10.3.3. UAE Virtual Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value & Volume
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Study Design
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Phase

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Medable, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. ICON, plc
• 15.3. Parexel International Corporation
• 15.4. Medidata Solutions Inc
• 15.5. Oracle Corp
• 15.6. Signant Health
• 15.7. Leo Laboratories Ltd
• 15.8. IQVIA Inc
• 15.9. PRA Health Sciences Inc
• 15.10. Clinical Ink Inc

16. Strategic Recommendations

17. About Us & Disclaimer